9 results about "Neuraminidase" patented technology

In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The present application relates to a kind of polyketide alkaloid hybrid compound and its preparation method and application, wherein, the polyketide alkaloid hybrid compound is selected from at least one of the compounds with the structural formula shown in formula I.The compound 1~6 structure includes an atypical angular anthracene ring polyketide ring and open-loop ternary nitrogen ring, both are novel compounds of skeleton.The polyketide alkaloid hybrid compound of the present application has the activity of inhibiting neuraminidase and influenza virus H1N1 and H3N2, and can be used for preparing anti-influenza virus drugs;Meanwhile, it also has the activity of resisting bacteria and actinomycetes, and can be used for preparing antibacterial agent, with good application prospect.

This invention discloses a neuraminidase-ROS dual-responsive nanocarrier, its preparation method, and its applications. The raw materials for the nanocarrier include 4-hydroxyphenylboronic acid pinacol ester, N,N'-carbonyldiimidazole, and polysialic acid; the molar ratio of 4-hydroxyphenylboronic acid pinacol ester to N,N'-carbonyldiimidazole is 1:1~3, and the mass ratio of 4-hydroxyphenylboronic acid pinacol ester to polysialic acid is 1:0.1~1. The neuraminidase-ROS dual-responsive nanocarrier of this invention not only efficiently delivers antibacterial and anti-inflammatory drugs, but the carrier itself can also actively regulate the pathological microenvironment (such as scavenging reactive oxygen species), thereby achieving multiple synergistic therapies and improving the overall efficacy against complex bacterial infections.

The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.

The present invention relates to compositions and methods for inducing an immune response against influenza virus in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding at least one influenza virus antigen, such as a hemagglutinin antigen or a fragment thereof, neuraminidase antigen or a fragment thereof, nucleoprotein antigen or a fragment thereof, matrix protein 1 antigen or a fragment thereof, or matrix-2 ion channel antigen or a fragment thereof.

Immunogenic compositions comprising hemagglutinin (HA) variants and / or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

This invention discloses an extract of Phyllanthus emblica, its preparation method, and its application, relating to the field of traditional Chinese medicine technology. The preparation method of the Phyllanthus emblica extract includes the following steps: S1. Extracting Phyllanthus emblica with a solvent to obtain an extract; S2. Centrifuging the extract, collecting the supernatant, then filtering it through a membrane to obtain a filtrate with a molecular weight below 1000D, concentrating it, and drying it to obtain the Phyllanthus emblica extract. This invention uses membrane separation technology to prepare an Phyllanthus emblica extract that inhibits coronavirus main protease (Mpro / 3Clpro), transmembrane serine protease 2 (Tmprss2), and neuraminidase (NA).